Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Oct;60(4):567-75.
doi: 10.1053/j.ajkd.2012.04.014. Epub 2012 May 22.

Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease

Jessica Kendrick  1 , Alfred K Cheung, James S Kaufman, Tom Greene, William L Roberts, Gerard Smits, Michel Chonchol; HOST (Homocysteinemia in Kidney and End Stage Renal Disease) Study Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease

Jessica Kendrick et al. Am J Kidney Dis. 2012 Oct.

Abstract

Background: Low vitamin D concentrations are prevalent in patients with chronic kidney disease (CKD). We investigated the relationship between plasma 25-hydroxyvitamin D (25[OH]D) or 1,25-dihydroxyvitamin D (1,25[OH](2)D) concentrations with death, cardiovascular events, and dialysis therapy initiation in patients with advanced CKD.

Study design: The HOST (Homocysteinemia in Kidney and End Stage Renal Disease) Study was a randomized double-blind trial evaluating the effects of high doses of folic acid on death and long-term dialysis therapy initiation in patients with advanced CKD (stages 4 and 5 not yet on dialysis therapy). 25(OH)D and 1,25(OH)(2)D were measured in stored plasma samples obtained 3 months after trial initiation and evaluated at clinically defined cutoffs (<10, 10-30, and >30 ng/mL) and tertiles (<15, 15-22, and >22 pg/mL), respectively. Cox proportional hazard models were used to examine the association between vitamin D concentrations and clinical outcomes.

Setting & participants: 1,099 patients with advanced CKD from 36 Veteran Affairs Medical Centers.

Predictors: 25(OH)D and 1,25(OH)(2)D concentrations.

Outcomes: Death, cardiovascular events, and time to initiation of long-term dialysis therapy.

Results: After a median follow-up of 2.9 years, 41% (n = 453) died, whereas 56% (n = 615) initiated dialysis therapy. Mean 25(OH)D and 1,25(OH)(2)D concentrations were 21 ± 10 ng/mL and 20 ± 11 pg/mL, respectively. After adjustment for potential confounders, the lowest tertile of 1,25(OH)(2)D was associated with death (HR, 1.33; 95% CI, 1.01-1.74) and initiation of long-term dialysis therapy (HR, 1.78; 95% CI, 1.40-2.26) compared with the highest tertile. The association with death and initiation of dialysis therapy was moderately attenuated after adjustment for plasma fibroblast growth factor 23 (FGF-23) concentrations (HRs of lower tertiles of 1.20 [95% CI, 0.91-1.58] and 1.56 [95% CI, 1.23-1.99], respectively, compared with highest tertile). There was no association between 25(OH)D concentrations and outcomes.

Limitations: Participants were mostly men.

Conclusions: Low plasma 1,25(OH)(2)D concentrations are associated with death and initiation of long-term dialysis therapy in patients with advanced CKD. FGF-23 level may attentuate this relationship.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Association of baseline plasma 25-hydroxyvitamin D concentrations with death within subgroups. Hazard ratio for every log increase in 25(OH)D. Error bars represent 95% confidence intervals. CVD=cardiovascular disease; iPTH=intact parathyroid hormone; FGF23=fibroblast growth factor 23.
Figure 2
Figure 2
Association of baseline plasma 1,25-dihydroxyvitamin D concentrations with death within subgroups. Hazard ratio for every log increase in 1,25(OH)2D. Error bars represent 95% confidence intervals. CVD=cardiovascular disease; iPTH=intact parathyroid hormone; FGF23=fibroblast growth factor 23.
See this image and copyright information in PMC

References

    1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047. - PubMed
    1. Keith DS, Nichols GA, Guillon CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Internal Med. 2004;164(6):659–663. - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. - PubMed
    1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. - PubMed
    1. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial. 2005;18(4):266–275. - PubMed

Publication types